outcome_descr,brand_descr,stratum,model,model_descr,term,HR,HR_CI,VE,VE_CI,HR_ECI,VE_ECI,diff,diff_CI,diff_ECI
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.57,(0.54-0.60), 43.0,(40.2-45.6),0.57 (0.54-0.60), 43.0 (40.2-45.6),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.61,(0.59-0.64), 38.7,(36.1-41.2),0.61 (0.59-0.64), 38.7 (36.1-41.2),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.67,(0.65-0.69), 32.9,(30.7-35.2),0.67 (0.65-0.69), 32.9 (30.7-35.2),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.69,(0.67-0.72), 30.9,(28.5-33.3),0.69 (0.67-0.72), 30.9 (28.5-33.3),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.68,(0.65-0.71), 31.8,(28.9-34.5),0.68 (0.65-0.71), 31.8 (28.9-34.5),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.67,(0.64-0.70), 32.8,(29.8-35.7),0.67 (0.64-0.70), 32.8 (29.8-35.7),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.66,(0.63-0.68), 34.5,(31.6-37.2),0.66 (0.63-0.68), 34.5 (31.6-37.2),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.57,(0.55-0.60), 42.8,(40.0-45.5),0.57 (0.55-0.60), 42.8 (40.0-45.5),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.62,(0.59-0.64), 38.5,(35.9-41.0),0.62 (0.59-0.64), 38.5 (35.9-41.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.67,(0.65-0.70), 32.7,(30.3-34.9),0.67 (0.65-0.70), 32.7 (30.3-34.9),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.69,(0.67-0.72), 30.6,(28.1-33.0),0.69 (0.67-0.72), 30.6 (28.1-33.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.69,(0.66-0.71), 31.4,(28.6-34.2),0.69 (0.66-0.71), 31.4 (28.6-34.2),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.68,(0.65-0.71), 32.4,(29.3-35.4),0.68 (0.65-0.71), 32.4 (29.3-35.4),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.66,(0.64-0.69), 33.6,(30.6-36.5),0.66 (0.64-0.69), 33.6 (30.6-36.5),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.59,(0.56-0.62), 41.1,(38.2-43.9),0.59 (0.56-0.62), 41.1 (38.2-43.9),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.64,(0.61-0.66), 36.5,(33.8-39.1),0.64 (0.61-0.66), 36.5 (33.8-39.1),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.70,(0.67-0.72), 30.5,(28.1-32.8),0.70 (0.67-0.72), 30.5 (28.1-32.8),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.71,(0.69-0.74), 28.5,(26.0-31.0),0.71 (0.69-0.74), 28.5 (26.0-31.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.71,(0.68-0.74), 29.3,(26.3-32.1),0.71 (0.68-0.74), 29.3 (26.3-32.1),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.70,(0.67-0.73), 30.5,(27.3-33.5),0.70 (0.67-0.73), 30.5 (27.3-33.5),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.68,(0.65-0.71), 32.1,(28.9-35.0),0.68 (0.65-0.71), 32.1 (28.9-35.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.57,(0.48-0.67), 43.3,(33.1-51.9),0.57 (0.48-0.67), 43.3 (33.1-51.9),-0.01,(-0.18-0.17),-0.01 (-0.18-0.17)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.57,(0.49-0.66), 43.2,(34.3-50.9),0.57 (0.49-0.66), 43.2 (34.3-50.9),-0.08,(-0.23-0.08),-0.08 (-0.23-0.08)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.66,(0.59-0.74), 33.8,(26.1-40.8),0.66 (0.59-0.74), 33.8 (26.1-40.8),-0.01,(-0.13-0.10),-0.01 (-0.13-0.10)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.67,(0.59-0.75), 33.4,(25.2-40.6),0.67 (0.59-0.75), 33.4 (25.2-40.6),-0.04,(-0.16-0.08),-0.04 (-0.16-0.08)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.64,(0.56-0.73), 35.9,(26.9-43.8),0.64 (0.56-0.73), 35.9 (26.9-43.8),-0.06,(-0.20-0.08),-0.06 (-0.20-0.08)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.66,(0.57-0.76), 34.0,(24.2-42.5),0.66 (0.57-0.76), 34.0 (24.2-42.5),-0.02,(-0.16-0.13),-0.02 (-0.16-0.13)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.64,(0.57-0.72), 36.0,(28.1-43.0),0.64 (0.57-0.72), 36.0 (28.1-43.0),-0.02,(-0.15-0.10),-0.02 (-0.15-0.10)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.57,(0.48-0.67), 42.8,(32.6-51.5),0.57 (0.48-0.67), 42.8 (32.6-51.5),0.00,(-0.17-0.17),0.00 (-0.17-0.17)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.57,(0.50-0.66), 42.7,(33.7-50.4),0.57 (0.50-0.66), 42.7 (33.7-50.4),-0.07,(-0.22-0.08),-0.07 (-0.22-0.08)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.67,(0.60-0.75), 33.1,(25.2-40.1),0.67 (0.60-0.75), 33.1 (25.2-40.1),-0.01,(-0.12-0.11),-0.01 (-0.12-0.11)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.68,(0.60-0.76), 32.5,(24.2-39.8),0.68 (0.60-0.76), 32.5 (24.2-39.8),-0.03,(-0.15-0.09),-0.03 (-0.15-0.09)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.65,(0.57-0.74), 34.7,(25.6-42.8),0.65 (0.57-0.74), 34.7 (25.6-42.8),-0.05,(-0.19-0.09),-0.05 (-0.19-0.09)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.67,(0.59-0.77), 32.7,(22.6-41.5),0.67 (0.59-0.77), 32.7 (22.6-41.5),0.00,(-0.15-0.14),0.00 (-0.15-0.14)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.66,(0.59-0.74), 34.1,(25.9-41.4),0.66 (0.59-0.74), 34.1 (25.9-41.4),-0.01,(-0.13-0.12),-0.01 (-0.13-0.12)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.58,(0.49-0.69), 41.7,(31.2-50.6),0.58 (0.49-0.69), 41.7 (31.2-50.6),-0.01,(-0.18-0.16),-0.01 (-0.18-0.16)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.59,(0.51-0.68), 40.8,(31.5-48.8),0.59 (0.51-0.68), 40.8 (31.5-48.8),-0.07,(-0.22-0.08),-0.07 (-0.22-0.08)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.69,(0.62-0.78), 30.6,(22.5-37.9),0.69 (0.62-0.78), 30.6 (22.5-37.9),0.00,(-0.12-0.11),0.00 (-0.12-0.11)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.70,(0.63-0.79), 29.9,(21.3-37.5),0.70 (0.63-0.79), 29.9 (21.3-37.5),-0.02,(-0.14-0.10),-0.02 (-0.14-0.10)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.68,(0.60-0.78), 31.8,(22.2-40.2),0.68 (0.60-0.78), 31.8 (22.2-40.2),-0.04,(-0.17-0.10),-0.04 (-0.17-0.10)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.71,(0.61-0.81), 29.3,(18.7-38.6),0.71 (0.61-0.81), 29.3 (18.7-38.6),0.02,(-0.13-0.16),0.02 (-0.13-0.16)
"Positive
SARS-CoV-2
test",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.69,(0.61-0.78), 31.0,(22.3-38.7),0.69 (0.61-0.78), 31.0 (22.3-38.7),0.02,(-0.11-0.14),0.02 (-0.11-0.14)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.48,(0.45-0.51), 52.3,(49.3-55.0),0.48 (0.45-0.51), 52.3 (49.3-55.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.57,(0.55-0.60), 42.6,(39.7-45.3),0.57 (0.55-0.60), 42.6 (39.7-45.3),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.62,(0.60-0.65), 37.7,(35.3-40.0),0.62 (0.60-0.65), 37.7 (35.3-40.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.65,(0.63-0.68), 34.6,(32.0-37.1),0.65 (0.63-0.68), 34.6 (32.0-37.1),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.68,(0.65-0.72), 31.7,(28.5-34.7),0.68 (0.65-0.72), 31.7 (28.5-34.7),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.72,(0.69-0.76), 27.6,(24.0-31.0),0.72 (0.69-0.76), 27.6 (24.0-31.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.73,(0.70-0.77), 26.6,(23.1-30.0),0.73 (0.70-0.77), 26.6 (23.1-30.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.49,(0.46-0.52), 51.2,(48.1-54.0),0.49 (0.46-0.52), 51.2 (48.1-54.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.59,(0.56-0.62), 41.2,(38.3-44.0),0.59 (0.56-0.62), 41.2 (38.3-44.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.64,(0.61-0.66), 36.3,(33.8-38.7),0.64 (0.61-0.66), 36.3 (33.8-38.7),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.67,(0.64-0.69), 33.4,(30.8-36.0),0.67 (0.64-0.69), 33.4 (30.8-36.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.69,(0.66-0.72), 30.8,(27.5-33.9),0.69 (0.66-0.72), 30.8 (27.5-33.9),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.73,(0.69-0.76), 27.3,(23.6-30.8),0.73 (0.69-0.76), 27.3 (23.6-30.8),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.72,(0.69-0.76), 27.7,(24.1-31.1),0.72 (0.69-0.76), 27.7 (24.1-31.1),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.51,(0.48-0.54), 49.1,(45.9-52.1),0.51 (0.48-0.54), 49.1 (45.9-52.1),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.61,(0.58-0.64), 38.8,(35.7-41.7),0.61 (0.58-0.64), 38.8 (35.7-41.7),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.67,(0.64-0.69), 33.3,(30.7-35.8),0.67 (0.64-0.69), 33.3 (30.7-35.8),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.70,(0.67-0.73), 30.1,(27.4-32.8),0.70 (0.67-0.73), 30.1 (27.4-32.8),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.74,(0.70-0.77), 26.4,(22.9-29.7),0.74 (0.70-0.77), 26.4 (22.9-29.7),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.77,(0.74-0.81), 22.7,(18.8-26.5),0.77 (0.74-0.81), 22.7 (18.8-26.5),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.76,(0.73-0.80), 23.6,(19.8-27.3),0.76 (0.73-0.80), 23.6 (19.8-27.3),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.46,(0.37-0.56), 54.4,(43.7-63.0),0.46 (0.37-0.56), 54.4 (43.7-63.0),-0.05,(-0.26-0.17),-0.05 (-0.26-0.17)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.54,(0.46-0.65), 45.5,(35.4-54.1),0.54 (0.46-0.65), 45.5 (35.4-54.1),-0.05,(-0.23-0.12),-0.05 (-0.23-0.12)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.63,(0.56-0.72), 36.9,(28.4-44.5),0.63 (0.56-0.72), 36.9 (28.4-44.5),0.01,(-0.12-0.14),0.01 (-0.12-0.14)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.65,(0.57-0.74), 34.8,(25.9-42.6),0.65 (0.57-0.74), 34.8 (25.9-42.6),0.00,(-0.14-0.13),0.00 (-0.14-0.13)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.67,(0.58-0.78), 32.9,(22.2-42.2),0.67 (0.58-0.78), 32.9 (22.2-42.2),-0.02,(-0.17-0.14),-0.02 (-0.17-0.14)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.79,(0.67-0.92), 21.4,(8.5-32.5),0.79 (0.67-0.92), 21.4 (8.5-32.5),0.08,(-0.08-0.24),0.08 (-0.08-0.24)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.73,(0.64-0.83), 27.3,(17.3-36.0),0.73 (0.64-0.83), 27.3 (17.3-36.0),-0.01,(-0.15-0.13),-0.01 (-0.15-0.13)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.47,(0.38-0.58), 53.3,(42.3-62.2),0.47 (0.38-0.58), 53.3 (42.3-62.2),-0.04,(-0.26-0.17),-0.04 (-0.26-0.17)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.56,(0.47-0.66), 44.2,(33.9-53.0),0.56 (0.47-0.66), 44.2 (33.9-53.0),-0.05,(-0.23-0.12),-0.05 (-0.23-0.12)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.65,(0.57-0.73), 35.4,(26.6-43.1),0.65 (0.57-0.73), 35.4 (26.6-43.1),0.01,(-0.12-0.15),0.01 (-0.12-0.15)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.67,(0.59-0.76), 33.3,(24.2-41.3),0.67 (0.59-0.76), 33.3 (24.2-41.3),0.00,(-0.13-0.14),0.00 (-0.13-0.14)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.69,(0.59-0.80), 31.4,(20.3-40.9),0.69 (0.59-0.80), 31.4 (20.3-40.9),-0.01,(-0.16-0.15),-0.01 (-0.16-0.15)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.80,(0.69-0.93), 19.9,(6.6-31.3),0.80 (0.69-0.93), 19.9 (6.6-31.3),0.10,(-0.07-0.26),0.10 (-0.07-0.26)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.73,(0.64-0.83), 26.8,(16.6-35.8),0.73 (0.64-0.83), 26.8 (16.6-35.8),0.01,(-0.13-0.15),0.01 (-0.13-0.15)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.49,(0.39-0.60), 51.4,(40.0-60.7),0.49 (0.39-0.60), 51.4 (40.0-60.7),-0.05,(-0.27-0.17),-0.05 (-0.27-0.17)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.58,(0.49-0.69), 42.2,(31.5-51.2),0.58 (0.49-0.69), 42.2 (31.5-51.2),-0.06,(-0.23-0.12),-0.06 (-0.23-0.12)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.68,(0.60-0.77), 31.9,(22.6-40.0),0.68 (0.60-0.77), 31.9 (22.6-40.0),0.02,(-0.11-0.15),0.02 (-0.11-0.15)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.71,(0.62-0.80), 29.5,(19.9-37.9),0.71 (0.62-0.80), 29.5 (19.9-37.9),0.01,(-0.12-0.14),0.01 (-0.12-0.14)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.73,(0.63-0.85), 26.7,(14.9-36.8),0.73 (0.63-0.85), 26.7 (14.9-36.8),0.00,(-0.16-0.15),0.00 (-0.16-0.15)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.86,(0.74-1.00), 13.9,(-0.5-26.2),0.86 (0.74-1.00), 13.9 (-0.5-26.2),0.11,(-0.05-0.27),0.11 (-0.05-0.27)
"Positive
SARS-CoV-2
test",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.78,(0.68-0.89), 22.3,(11.2-32.0),0.78 (0.68-0.89), 22.3 (11.2-32.0),0.02,(-0.12-0.16),0.02 (-0.12-0.16)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.80,(0.74-0.86), 20.0,(13.6-26.0),0.80 (0.74-0.86), 20.0 (13.6-26.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.71,(0.66-0.77), 28.6,(23.1-33.8),0.71 (0.66-0.77), 28.6 (23.1-33.8),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.83,(0.78-0.88), 17.2,(12.0-22.1),0.83 (0.78-0.88), 17.2 (12.0-22.1),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.90,(0.84-0.96), 10.4,(4.3-16.1),0.90 (0.84-0.96), 10.4 (4.3-16.1),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.88,(0.82-0.94), 12.4,(6.0-18.5),0.88 (0.82-0.94), 12.4 (6.0-18.5),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.82,(0.76-0.88), 18.4,(11.9-24.5),0.82 (0.76-0.88), 18.4 (11.9-24.5),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.84,(0.78-0.90), 16.3,(10.1-22.0),0.84 (0.78-0.90), 16.3 (10.1-22.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.77,(0.71-0.83), 23.4,(17.2-29.2),0.77 (0.71-0.83), 23.4 (17.2-29.2),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.68,(0.63-0.73), 31.8,(26.6-36.7),0.68 (0.63-0.73), 31.8 (26.6-36.7),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.79,(0.74-0.84), 21.4,(16.4-26.1),0.79 (0.74-0.84), 21.4 (16.4-26.1),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.84,(0.79-0.90), 15.7,(9.9-21.2),0.84 (0.79-0.90), 15.7 (9.9-21.2),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.82,(0.76-0.88), 18.3,(12.1-24.0),0.82 (0.76-0.88), 18.3 (12.1-24.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.76,(0.70-0.82), 24.2,(17.9-29.9),0.76 (0.70-0.82), 24.2 (17.9-29.9),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.79,(0.73-0.85), 21.3,(15.2-27.0),0.79 (0.73-0.85), 21.3 (15.2-27.0),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.88,(0.81-0.96), 12.1,(4.1-19.5),0.88 (0.81-0.96), 12.1 (4.1-19.5),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.78,(0.72-0.85), 21.9,(15.0-28.3),0.78 (0.72-0.85), 21.9 (15.0-28.3),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.91,(0.85-0.97),  8.9,(2.7-14.7),0.91 (0.85-0.97),  8.9 (2.7-14.7),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.94,(0.88-1.01),  5.6,(-1.1-11.8),0.94 (0.88-1.01),  5.6 (-1.1-11.8),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.91,(0.84-0.98),  8.9,(1.8-15.5),0.91 (0.84-0.98),  8.9 (1.8-15.5),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.83,(0.76-0.90), 17.3,(10.2-23.8),0.83 (0.76-0.90), 17.3 (10.2-23.8),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.83,(0.77-0.90), 16.6,(9.9-22.8),0.83 (0.77-0.90), 16.6 (9.9-22.8),0.00,(NA-NA),0.00 (NA-NA)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.87,(0.67-1.14), 12.6,(-13.9-32.9),0.87 (0.67-1.14), 12.6 (-13.9-32.9),0.09,(-0.19-0.37),0.09 (-0.19-0.37)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.66,(0.50-0.86), 34.2,(13.9-49.7),0.66 (0.50-0.86), 34.2 (13.9-49.7),-0.08,(-0.36-0.20),-0.08 (-0.36-0.20)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.81,(0.66-0.99), 19.2,(0.5-34.4),0.81 (0.66-0.99), 19.2 (0.5-34.4),-0.02,(-0.24-0.19),-0.02 (-0.24-0.19)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.80,(0.65-1.00), 19.6,(-0.1-35.5),0.80 (0.65-1.00), 19.6 (-0.1-35.5),-0.11,(-0.34-0.12),-0.11 (-0.34-0.12)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.75,(0.59-0.94), 25.3,(5.7-40.9),0.75 (0.59-0.94), 25.3 (5.7-40.9),-0.16,(-0.40-0.08),-0.16 (-0.40-0.08)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.60,(0.46-0.77), 40.4,(22.6-54.2),0.60 (0.46-0.77), 40.4 (22.6-54.2),-0.31,(-0.59--0.04),-0.31 (-0.59--0.04)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.79,(0.65-0.96), 21.0,(3.8-35.1),0.79 (0.65-0.96), 21.0 (3.8-35.1),-0.06,(-0.27-0.15),-0.06 (-0.27-0.15)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.86,(0.66-1.12), 14.1,(-12.0-34.1),0.86 (0.66-1.12), 14.1 (-12.0-34.1),0.12,(-0.16-0.39),0.12 (-0.16-0.39)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.65,(0.50-0.85), 35.1,(15.1-50.4),0.65 (0.50-0.85), 35.1 (15.1-50.4),-0.05,(-0.33-0.23),-0.05 (-0.33-0.23)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.80,(0.65-0.98), 20.2,(1.6-35.2),0.80 (0.65-0.98), 20.2 (1.6-35.2),0.02,(-0.20-0.23),0.02 (-0.20-0.23)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.80,(0.64-0.99), 20.4,(0.7-36.2),0.80 (0.64-0.99), 20.4 (0.7-36.2),-0.06,(-0.29-0.17),-0.06 (-0.29-0.17)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.74,(0.58-0.94), 26.0,(6.2-41.6),0.74 (0.58-0.94), 26.0 (6.2-41.6),-0.10,(-0.35-0.15),-0.10 (-0.35-0.15)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.59,(0.45-0.77), 40.9,(22.9-54.7),0.59 (0.45-0.77), 40.9 (22.9-54.7),-0.25,(-0.53-0.03),-0.25 (-0.53-0.03)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.79,(0.65-0.97), 20.7,(2.6-35.4),0.79 (0.65-0.97), 20.7 (2.6-35.4),0.01,(-0.21-0.23),0.01 (-0.21-0.23)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.96,(0.74-1.26),  3.6,(-25.9-26.1),0.96 (0.74-1.26),  3.6 (-25.9-26.1),0.09,(-0.19-0.37),0.09 (-0.19-0.37)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.74,(0.57-0.97), 25.7,(2.7-43.3),0.74 (0.57-0.97), 25.7 (2.7-43.3),-0.05,(-0.33-0.23),-0.05 (-0.33-0.23)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.89,(0.72-1.10), 11.2,(-9.8-28.2),0.89 (0.72-1.10), 11.2 (-9.8-28.2),-0.03,(-0.25-0.20),-0.03 (-0.25-0.20)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.88,(0.70-1.10), 11.8,(-10.5-29.5),0.88 (0.70-1.10), 11.8 (-10.5-29.5),-0.07,(-0.30-0.17),-0.07 (-0.30-0.17)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.81,(0.63-1.03), 19.2,(-2.8-36.5),0.81 (0.63-1.03), 19.2 (-2.8-36.5),-0.12,(-0.37-0.13),-0.12 (-0.37-0.13)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.64,(0.49-0.84), 36.0,(16.1-51.2),0.64 (0.49-0.84), 36.0 (16.1-51.2),-0.26,(-0.54-0.03),-0.26 (-0.54-0.03)
"Positive
SARS-CoV-2
test",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.86,(0.69-1.06), 14.2,(-6.1-30.6),0.86 (0.69-1.06), 14.2 (-6.1-30.6),0.03,(-0.20-0.25),0.03 (-0.20-0.25)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.27,(0.24-0.32), 72.5,(68.5-76.0),0.27 (0.24-0.32), 72.5 (68.5-76.0),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.31,(0.27-0.34), 69.3,(65.6-72.6),0.31 (0.27-0.34), 69.3 (65.6-72.6),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.29,(0.26-0.31), 71.5,(68.7-74.1),0.29 (0.26-0.31), 71.5 (68.7-74.1),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.23,(0.20-0.25), 77.5,(74.9-79.8),0.23 (0.20-0.25), 77.5 (74.9-79.8),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.19,(0.17-0.22), 80.9,(78.1-83.3),0.19 (0.17-0.22), 80.9 (78.1-83.3),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.15,(0.12-0.17), 85.3,(82.6-87.5),0.15 (0.12-0.17), 85.3 (82.6-87.5),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.15,(0.13-0.17), 84.9,(82.8-86.7),0.15 (0.13-0.17), 84.9 (82.8-86.7),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.29,(0.26-0.34), 70.6,(66.3-74.4),0.29 (0.26-0.34), 70.6 (66.3-74.4),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.33,(0.30-0.37), 66.8,(62.7-70.3),0.33 (0.30-0.37), 66.8 (62.7-70.3),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.31,(0.28-0.34), 68.6,(65.5-71.5),0.31 (0.28-0.34), 68.6 (65.5-71.5),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.25,(0.23-0.28), 74.9,(71.9-77.5),0.25 (0.23-0.28), 74.9 (71.9-77.5),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.22,(0.19-0.25), 78.2,(75.0-81.0),0.22 (0.19-0.25), 78.2 (75.0-81.0),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.17,(0.14-0.20), 83.1,(80.0-85.7),0.17 (0.14-0.20), 83.1 (80.0-85.7),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.17,(0.15-0.20), 82.6,(80.2-84.8),0.17 (0.15-0.20), 82.6 (80.2-84.8),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.31,(0.27-0.36), 69.0,(64.4-73.0),0.31 (0.27-0.36), 69.0 (64.4-73.0),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.36,(0.32-0.40), 64.2,(59.9-68.1),0.36 (0.32-0.40), 64.2 (59.9-68.1),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.34,(0.30-0.37), 66.5,(63.1-69.6),0.34 (0.30-0.37), 66.5 (63.1-69.6),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.26,(0.24-0.30), 73.6,(70.5-76.3),0.26 (0.24-0.30), 73.6 (70.5-76.3),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.23,(0.20-0.27), 76.7,(73.3-79.7),0.23 (0.20-0.27), 76.7 (73.3-79.7),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.18,(0.15-0.21), 81.9,(78.6-84.7),0.18 (0.15-0.21), 81.9 (78.6-84.7),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.19,(0.16-0.21), 81.4,(78.8-83.8),0.19 (0.16-0.21), 81.4 (78.8-83.8),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.28,(0.18-0.44), 72.0,(56.2-82.1),0.28 (0.18-0.44), 72.0 (56.2-82.1),0.02,(-0.45-0.49),0.02 (-0.45-0.49)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.38,(0.27-0.53), 62.2,(46.9-73.1),0.38 (0.27-0.53), 62.2 (46.9-73.1),0.21,(-0.15-0.57),0.21 (-0.15-0.57)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.29,(0.21-0.39), 71.4,(61.2-78.8),0.29 (0.21-0.39), 71.4 (61.2-78.8),0.00,(-0.31-0.32),0.00 (-0.31-0.32)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.23,(0.17-0.33), 76.5,(66.7-83.5),0.23 (0.17-0.33), 76.5 (66.7-83.5),0.04,(-0.33-0.41),0.04 (-0.33-0.41)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.11,(0.07-0.20), 88.5,(80.2-93.3),0.11 (0.07-0.20), 88.5 (80.2-93.3),-0.51,(-1.07-0.05),-0.51 (-1.07-0.05)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.17,(0.10-0.28), 82.8,(72.0-89.5),0.17 (0.10-0.28), 82.8 (72.0-89.5),0.15,(-0.37-0.67),0.15 (-0.37-0.67)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.12,(0.08-0.18), 87.7,(82.1-91.6),0.12 (0.08-0.18), 87.7 (82.1-91.6),-0.21,(-0.61-0.19),-0.21 (-0.61-0.19)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.29,(0.19-0.46), 70.5,(53.9-81.2),0.29 (0.19-0.46), 70.5 (53.9-81.2),0.00,(-0.46-0.47),0.00 (-0.46-0.47)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.40,(0.29-0.56), 59.9,(43.6-71.4),0.40 (0.29-0.56), 59.9 (43.6-71.4),0.19,(-0.17-0.55),0.19 (-0.17-0.55)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.31,(0.23-0.42), 69.1,(58.3-77.1),0.31 (0.23-0.42), 69.1 (58.3-77.1),-0.02,(-0.33-0.30),-0.02 (-0.33-0.30)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.26,(0.18-0.36), 74.4,(63.7-81.9),0.26 (0.18-0.36), 74.4 (63.7-81.9),0.02,(-0.34-0.38),0.02 (-0.34-0.38)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.13,(0.07-0.22), 87.2,(78.0-92.6),0.13 (0.07-0.22), 87.2 (78.0-92.6),-0.53,(-1.09-0.03),-0.53 (-1.09-0.03)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.19,(0.12-0.31), 80.8,(68.6-88.3),0.19 (0.12-0.31), 80.8 (68.6-88.3),0.13,(-0.39-0.65),0.13 (-0.39-0.65)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.14,(0.09-0.20), 86.1,(79.6-90.5),0.14 (0.09-0.20), 86.1 (79.6-90.5),-0.22,(-0.63-0.18),-0.22 (-0.63-0.18)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.31,(0.20-0.48), 69.2,(51.6-80.4),0.31 (0.20-0.48), 69.2 (51.6-80.4),-0.01,(-0.48-0.47),-0.01 (-0.48-0.47)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.43,(0.31-0.61), 56.6,(38.8-69.2),0.43 (0.31-0.61), 56.6 (38.8-69.2),0.19,(-0.17-0.56),0.19 (-0.17-0.56)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.33,(0.24-0.44), 67.2,(55.6-75.8),0.33 (0.24-0.44), 67.2 (55.6-75.8),-0.02,(-0.34-0.30),-0.02 (-0.34-0.30)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.28,(0.20-0.39), 72.3,(60.7-80.5),0.28 (0.20-0.39), 72.3 (60.7-80.5),0.05,(-0.32-0.41),0.05 (-0.32-0.41)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.14,(0.08-0.24), 86.1,(76.1-92.0),0.14 (0.08-0.24), 86.1 (76.1-92.0),-0.52,(-1.08-0.04),-0.52 (-1.08-0.04)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.20,(0.12-0.33), 79.9,(66.9-87.8),0.20 (0.12-0.33), 79.9 (66.9-87.8),0.11,(-0.42-0.63),0.11 (-0.42-0.63)
"COVID-19
hospitalisation",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.15,(0.10-0.23), 84.7,(77.4-89.7),0.15 (0.10-0.23), 84.7 (77.4-89.7),-0.19,(-0.61-0.22),-0.19 (-0.61-0.22)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.18,(0.15-0.22), 82.0,(78.1-85.2),0.18 (0.15-0.22), 82.0 (78.1-85.2),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.27,(0.23-0.31), 73.0,(69.0-76.5),0.27 (0.23-0.31), 73.0 (69.0-76.5),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.27,(0.24-0.30), 73.1,(70.0-75.9),0.27 (0.24-0.30), 73.1 (70.0-75.9),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.22,(0.19-0.24), 78.4,(75.6-80.9),0.22 (0.19-0.24), 78.4 (75.6-80.9),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.19,(0.16-0.23), 80.7,(77.5-83.5),0.19 (0.16-0.23), 80.7 (77.5-83.5),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.15,(0.12-0.18), 85.0,(81.8-87.6),0.15 (0.12-0.18), 85.0 (81.8-87.6),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.17,(0.14-0.19), 83.4,(80.7-85.6),0.17 (0.14-0.19), 83.4 (80.7-85.6),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.20,(0.16-0.24), 80.1,(75.8-83.6),0.20 (0.16-0.24), 80.1 (75.8-83.6),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.30,(0.26-0.35), 69.9,(65.3-73.8),0.30 (0.26-0.35), 69.9 (65.3-73.8),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.30,(0.27-0.34), 69.7,(66.2-72.9),0.30 (0.27-0.34), 69.7 (66.2-72.9),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.24,(0.22-0.28), 75.7,(72.5-78.5),0.24 (0.22-0.28), 75.7 (72.5-78.5),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.22,(0.19-0.26), 78.0,(74.3-81.2),0.22 (0.19-0.26), 78.0 (74.3-81.2),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.17,(0.14-0.21), 82.9,(79.2-85.9),0.17 (0.14-0.21), 82.9 (79.2-85.9),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.18,(0.16-0.21), 81.6,(78.6-84.2),0.18 (0.16-0.21), 81.6 (78.6-84.2),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.22,(0.18-0.27), 77.9,(73.0-81.9),0.22 (0.18-0.27), 77.9 (73.0-81.9),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.33,(0.28-0.38), 67.3,(62.3-71.6),0.33 (0.28-0.38), 67.3 (62.3-71.6),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.33,(0.29-0.37), 67.0,(63.1-70.5),0.33 (0.29-0.37), 67.0 (63.1-70.5),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.26,(0.23-0.29), 74.0,(70.5-77.0),0.26 (0.23-0.29), 74.0 (70.5-77.0),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.24,(0.21-0.28), 75.7,(71.6-79.3),0.24 (0.21-0.28), 75.7 (71.6-79.3),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.19,(0.16-0.23), 80.9,(76.7-84.3),0.19 (0.16-0.23), 80.9 (76.7-84.3),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.21,(0.18-0.24), 79.2,(75.8-82.2),0.21 (0.18-0.24), 79.2 (75.8-82.2),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.23,(0.13-0.41), 77.1,(59.4-87.1),0.23 (0.13-0.41), 77.1 (59.4-87.1),0.24,(-0.36-0.85),0.24 (-0.36-0.85)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.29,(0.19-0.45), 71.0,(54.9-81.4),0.29 (0.19-0.45), 71.0 (54.9-81.4),0.07,(-0.39-0.53),0.07 (-0.39-0.53)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.29,(0.21-0.41), 70.7,(58.7-79.2),0.29 (0.21-0.41), 70.7 (58.7-79.2),0.09,(-0.27-0.44),0.09 (-0.27-0.44)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.21,(0.14-0.32), 79.2,(68.3-86.4),0.21 (0.14-0.32), 79.2 (68.3-86.4),-0.04,(-0.48-0.40),-0.04 (-0.48-0.40)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.12,(0.06-0.22), 88.4,(77.6-94.0),0.12 (0.06-0.22), 88.4 (77.6-94.0),-0.51,(-1.18-0.17),-0.51 (-1.18-0.17)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.23,(0.14-0.39), 76.9,(60.6-86.5),0.23 (0.14-0.39), 76.9 (60.6-86.5),0.43,(-0.14-1.00),0.43 (-0.14-1.00)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.18,(0.12-0.28), 81.5,(71.8-87.9),0.18 (0.12-0.28), 81.5 (71.8-87.9),0.10,(-0.34-0.55),0.10 (-0.34-0.55)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.25,(0.14-0.44), 75.1,(55.8-86.0),0.25 (0.14-0.44), 75.1 (55.8-86.0),0.22,(-0.38-0.83),0.22 (-0.38-0.83)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.32,(0.20-0.49), 68.3,(50.6-79.6),0.32 (0.20-0.49), 68.3 (50.6-79.6),0.05,(-0.41-0.52),0.05 (-0.41-0.52)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.32,(0.23-0.46), 67.6,(54.5-76.9),0.32 (0.23-0.46), 67.6 (54.5-76.9),0.07,(-0.29-0.43),0.07 (-0.29-0.43)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.23,(0.15-0.35), 76.9,(64.9-84.8),0.23 (0.15-0.35), 76.9 (64.9-84.8),-0.05,(-0.49-0.38),-0.05 (-0.49-0.38)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.13,(0.07-0.25), 86.9,(74.9-93.2),0.13 (0.07-0.25), 86.9 (74.9-93.2),-0.52,(-1.19-0.15),-0.52 (-1.19-0.15)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.26,(0.15-0.44), 74.1,(55.7-84.8),0.26 (0.15-0.44), 74.1 (55.7-84.8),0.42,(-0.15-0.99),0.42 (-0.15-0.99)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.21,(0.13-0.31), 79.5,(68.6-86.6),0.21 (0.13-0.31), 79.5 (68.6-86.6),0.11,(-0.34-0.56),0.11 (-0.34-0.56)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.27,(0.15-0.49), 72.9,(51.0-85.0),0.27 (0.15-0.49), 72.9 (51.0-85.0),0.21,(-0.42-0.83),0.21 (-0.42-0.83)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.33,(0.21-0.51), 67.0,(48.7-78.8),0.33 (0.21-0.51), 67.0 (48.7-78.8),0.01,(-0.46-0.47),0.01 (-0.46-0.47)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.35,(0.25-0.49), 65.0,(50.6-75.2),0.35 (0.25-0.49), 65.0 (50.6-75.2),0.06,(-0.30-0.42),0.06 (-0.30-0.42)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.27,(0.17-0.41), 73.4,(59.4-82.6),0.27 (0.17-0.41), 73.4 (59.4-82.6),0.02,(-0.42-0.46),0.02 (-0.42-0.46)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.14,(0.07-0.27), 86.0,(72.9-92.7),0.14 (0.07-0.27), 86.0 (72.9-92.7),-0.55,(-1.22-0.13),-0.55 (-1.22-0.13)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.27,(0.16-0.47), 72.8,(53.2-84.2),0.27 (0.16-0.47), 72.8 (53.2-84.2),0.35,(-0.23-0.93),0.35 (-0.23-0.93)
"COVID-19
hospitalisation",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.23,(0.15-0.35), 77.4,(64.8-85.4),0.23 (0.15-0.35), 77.4 (64.8-85.4),0.08,(-0.38-0.55),0.08 (-0.38-0.55)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.49,(0.40-0.59), 51.1,(40.7-59.6),0.49 (0.40-0.59), 51.1 (40.7-59.6),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.39,(0.32-0.47), 61.3,(53.1-68.0),0.39 (0.32-0.47), 61.3 (53.1-68.0),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.33,(0.28-0.39), 67.0,(60.8-72.2),0.33 (0.28-0.39), 67.0 (60.8-72.2),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.28,(0.23-0.35), 71.7,(65.2-77.0),0.28 (0.23-0.35), 71.7 (65.2-77.0),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.25,(0.20-0.32), 75.0,(67.9-80.5),0.25 (0.20-0.32), 75.0 (67.9-80.5),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.22,(0.16-0.30), 77.9,(69.9-83.7),0.22 (0.16-0.30), 77.9 (69.9-83.7),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.26,(0.20-0.33), 74.5,(67.1-80.2),0.26 (0.20-0.33), 74.5 (67.1-80.2),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.49,(0.40-0.59), 51.0,(40.7-59.6),0.49 (0.40-0.59), 51.0 (40.7-59.6),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.39,(0.32-0.48), 60.7,(52.4-67.5),0.39 (0.32-0.48), 60.7 (52.4-67.5),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.34,(0.29-0.40), 66.0,(59.6-71.4),0.34 (0.29-0.40), 66.0 (59.6-71.4),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.29,(0.24-0.36), 70.5,(63.8-76.0),0.29 (0.24-0.36), 70.5 (63.8-76.0),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.26,(0.20-0.34), 73.9,(66.5-79.6),0.26 (0.20-0.34), 73.9 (66.5-79.6),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.23,(0.17-0.32), 76.8,(68.5-82.9),0.23 (0.17-0.32), 76.8 (68.5-82.9),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.27,(0.21-0.35), 73.0,(65.1-79.0),0.27 (0.21-0.35), 73.0 (65.1-79.0),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.53,(0.42-0.67), 46.6,(32.5-57.8),0.53 (0.42-0.67), 46.6 (32.5-57.8),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.41,(0.34-0.50), 59.1,(50.0-66.5),0.41 (0.34-0.50), 59.1 (50.0-66.5),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.40,(0.33-0.48), 60.3,(52.5-66.9),0.40 (0.33-0.48), 60.3 (52.5-66.9),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.34,(0.27-0.41), 66.4,(58.5-72.8),0.34 (0.27-0.41), 66.4 (58.5-72.8),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.32,(0.24-0.43), 67.8,(56.8-76.0),0.32 (0.24-0.43), 67.8 (56.8-76.0),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.27,(0.20-0.37), 73.2,(63.4-80.4),0.27 (0.20-0.37), 73.2 (63.4-80.4),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.30,(0.23-0.40), 69.6,(60.4-76.6),0.30 (0.23-0.40), 69.6 (60.4-76.6),0.00,(NA-NA),0.00 (NA-NA)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.39,(0.19-0.79), 61.2,(20.9-81.0),0.39 (0.19-0.79), 61.2 (20.9-81.0),-0.23,(-0.97-0.51),-0.23 (-0.97-0.51)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.60,(0.35-1.02), 40.3,(-1.9-65.1),0.60 (0.35-1.02), 40.3 (-1.9-65.1),0.43,(-0.14-1.00),0.43 (-0.14-1.00)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.28,(0.15-0.51), 72.1,(48.7-84.8),0.28 (0.15-0.51), 72.1 (48.7-84.8),-0.17,(-0.80-0.47),-0.17 (-0.80-0.47)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.38,(0.21-0.68), 62.2,(31.6-79.1),0.38 (0.21-0.68), 62.2 (31.6-79.1),0.29,(-0.34-0.92),0.29 (-0.34-0.92)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.16,(0.06-0.40), 84.3,(60.0-93.8),0.16 (0.06-0.40), 84.3 (60.0-93.8),-0.46,(-1.43-0.50),-0.46 (-1.43-0.50)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.10,(0.03-0.34), 89.5,(65.7-96.8),0.10 (0.03-0.34), 89.5 (65.7-96.8),-0.75,(-1.97-0.48),-0.75 (-1.97-0.48)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.08,(0.03-0.20), 92.0,(79.6-96.8),0.08 (0.03-0.20), 92.0 (79.6-96.8),-1.15,(-2.12--0.19),-1.15 (-2.12--0.19)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.39,(0.19-0.80), 60.6,(19.6-80.7),0.39 (0.19-0.80), 60.6 (19.6-80.7),-0.22,(-0.96-0.52),-0.22 (-0.96-0.52)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.61,(0.36-1.05), 38.7,(-4.7-64.1),0.61 (0.36-1.05), 38.7 (-4.7-64.1),0.44,(-0.12-1.01),0.44 (-0.12-1.01)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.29,(0.16-0.53), 71.0,(46.6-84.3),0.29 (0.16-0.53), 71.0 (46.6-84.3),-0.16,(-0.79-0.47),-0.16 (-0.79-0.47)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.39,(0.22-0.71), 60.6,(28.9-78.2),0.39 (0.22-0.71), 60.6 (28.9-78.2),0.29,(-0.34-0.92),0.29 (-0.34-0.92)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.16,(0.06-0.41), 83.8,(58.9-93.6),0.16 (0.06-0.41), 83.8 (58.9-93.6),-0.48,(-1.44-0.49),-0.48 (-1.44-0.49)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.11,(0.03-0.35), 89.2,(64.8-96.7),0.11 (0.03-0.35), 89.2 (64.8-96.7),-0.76,(-1.98-0.46),-0.76 (-1.98-0.46)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.08,(0.03-0.21), 91.6,(78.5-96.7),0.08 (0.03-0.21), 91.6 (78.5-96.7),-1.17,(-2.14--0.20),-1.17 (-2.14--0.20)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.43,(0.21-0.89), 56.6,(11.4-78.7),0.43 (0.21-0.89), 56.6 (11.4-78.7),-0.21,(-0.96-0.54),-0.21 (-0.96-0.54)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.62,(0.36-1.07), 37.6,(-7.3-63.7),0.62 (0.36-1.07), 37.6 (-7.3-63.7),0.42,(-0.15-1.00),0.42 (-0.15-1.00)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.31,(0.17-0.58), 68.7,(42.2-83.1),0.31 (0.17-0.58), 68.7 (42.2-83.1),-0.24,(-0.88-0.40),-0.24 (-0.88-0.40)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.41,(0.22-0.74), 59.4,(25.6-77.9),0.41 (0.22-0.74), 59.4 (25.6-77.9),0.19,(-0.45-0.83),0.19 (-0.45-0.83)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.18,(0.07-0.47), 81.6,(53.1-92.8),0.18 (0.07-0.47), 81.6 (53.1-92.8),-0.56,(-1.54-0.42),-0.56 (-1.54-0.42)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.11,(0.03-0.37), 89.0,(63.5-96.7),0.11 (0.03-0.37), 89.0 (63.5-96.7),-0.89,(-2.12-0.35),-0.89 (-2.12-0.35)
"COVID-19
hospitalisation",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.10,(0.04-0.24), 90.5,(75.8-96.3),0.10 (0.04-0.24), 90.5 (75.8-96.3),-1.16,(-2.13--0.19),-1.16 (-2.13--0.19)
COVID-19 death,Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.01,(0.00-0.02), 99.5,(98.4-99.8),0.01 (0.00-0.02), 99.5 (98.4-99.8),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.01,(0.00-0.02), 99.1,(98.3-99.6),0.01 (0.00-0.02), 99.1 (98.3-99.6),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.01,(0.01-0.02), 98.9,(98.3-99.3),0.01 (0.01-0.02), 98.9 (98.3-99.3),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.01,(0.01-0.02), 98.8,(98.2-99.1),0.01 (0.01-0.02), 98.8 (98.2-99.1),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.01,(0.00-0.01), 99.2,(98.7-99.5),0.01 (0.00-0.01), 99.2 (98.7-99.5),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.00,(0.00-0.01), 99.5,(99.1-99.8),0.00 (0.00-0.01), 99.5 (99.1-99.8),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.00,(0.00-0.01), 99.7,(99.5-99.8),0.00 (0.00-0.01), 99.7 (99.5-99.8),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.01,(0.00-0.02), 99.5,(98.3-99.8),0.01 (0.00-0.02), 99.5 (98.3-99.8),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.01,(0.00-0.02), 99.1,(98.1-99.5),0.01 (0.00-0.02), 99.1 (98.1-99.5),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.01,(0.01-0.02), 98.8,(98.1-99.2),0.01 (0.01-0.02), 98.8 (98.1-99.2),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.01,(0.01-0.02), 98.6,(98.0-99.0),0.01 (0.01-0.02), 98.6 (98.0-99.0),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.01,(0.01-0.01), 99.1,(98.5-99.4),0.01 (0.01-0.01), 99.1 (98.5-99.4),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.01,(0.00-0.01), 99.5,(99.0-99.7),0.01 (0.00-0.01), 99.5 (99.0-99.7),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.00,(0.00-0.01), 99.7,(99.4-99.8),0.00 (0.00-0.01), 99.7 (99.4-99.8),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.01,(0.00-0.02), 99.4,(98.3-99.8),0.01 (0.00-0.02), 99.4 (98.3-99.8),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.01,(0.01-0.02), 99.0,(97.9-99.5),0.01 (0.01-0.02), 99.0 (97.9-99.5),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.01,(0.01-0.02), 98.5,(97.7-99.0),0.01 (0.01-0.02), 98.5 (97.7-99.0),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.01,(0.01-0.02), 98.5,(97.8-99.0),0.01 (0.01-0.02), 98.5 (97.8-99.0),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.01,(0.01-0.02), 99.0,(98.4-99.4),0.01 (0.01-0.02), 99.0 (98.4-99.4),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.01,(0.00-0.01), 99.4,(98.8-99.7),0.01 (0.00-0.01), 99.4 (98.8-99.7),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.00,(0.00-0.01), 99.6,(99.4-99.8),0.00 (0.00-0.01), 99.6 (99.4-99.8),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-10.44,(-11.58--9.30),-10.44 (-11.58--9.30)
COVID-19 death,Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.01,(0.00-0.07), 99.1,(93.3-99.9),0.01 (0.00-0.07), 99.1 (93.3-99.9),0.08,(-2.00-2.16),0.08 (-2.00-2.16)
COVID-19 death,Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.01,(0.00-0.03), 99.1,(96.5-99.8),0.01 (0.00-0.03), 99.1 (96.5-99.8),-0.26,(-1.71-1.19),-0.26 (-1.71-1.19)
COVID-19 death,Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.02,(0.01-0.05), 98.1,(95.4-99.2),0.02 (0.01-0.05), 98.1 (95.4-99.2),0.42,(-0.55-1.39),0.42 (-0.55-1.39)
COVID-19 death,Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.00,(0.00-0.03), 99.6,(97.1-99.9),0.00 (0.00-0.03), 99.6 (97.1-99.9),-0.68,(-2.71-1.35),-0.68 (-2.71-1.35)
COVID-19 death,Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.01,(0.00-0.04), 99.0,(96.1-99.8),0.01 (0.00-0.04), 99.0 (96.1-99.8),0.70,(-0.85-2.25),0.70 (-0.85-2.25)
COVID-19 death,Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.00,(0.00-0.01), 99.8,(98.6-100.0),0.00 (0.00-0.01), 99.8 (98.6-100.0),-0.44,(-2.47-1.58),-0.44 (-2.47-1.58)
COVID-19 death,Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-10.39,(-11.53--9.26),-10.39 (-11.53--9.26)
COVID-19 death,Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.01,(0.00-0.07), 99.0,(92.8-99.9),0.01 (0.00-0.07), 99.0 (92.8-99.9),0.07,(-2.01-2.16),0.07 (-2.01-2.16)
COVID-19 death,Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.01,(0.00-0.04), 99.0,(96.2-99.8),0.01 (0.00-0.04), 99.0 (96.2-99.8),-0.26,(-1.72-1.19),-0.26 (-1.72-1.19)
COVID-19 death,Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.02,(0.01-0.05), 97.9,(94.8-99.1),0.02 (0.01-0.05), 97.9 (94.8-99.1),0.42,(-0.56-1.39),0.42 (-0.56-1.39)
COVID-19 death,Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.00,(0.00-0.03), 99.5,(96.7-99.9),0.00 (0.00-0.03), 99.5 (96.7-99.9),-0.68,(-2.72-1.35),-0.68 (-2.72-1.35)
COVID-19 death,Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.01,(0.00-0.04), 98.9,(95.6-99.7),0.01 (0.00-0.04), 98.9 (95.6-99.7),0.69,(-0.86-2.24),0.69 (-0.86-2.24)
COVID-19 death,Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.00,(0.00-0.02), 99.8,(98.4-100.0),0.00 (0.00-0.02), 99.8 (98.4-100.0),-0.45,(-2.48-1.58),-0.45 (-2.48-1.58)
COVID-19 death,Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-10.39,(-11.53--9.25),-10.39 (-11.53--9.25)
COVID-19 death,Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.01,(0.00-0.07), 99.0,(92.6-99.9),0.01 (0.00-0.07), 99.0 (92.6-99.9),0.00,(-2.09-2.09),0.00 (-2.09-2.09)
COVID-19 death,Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.01,(0.00-0.04), 99.0,(96.1-99.8),0.01 (0.00-0.04), 99.0 (96.1-99.8),-0.41,(-1.87-1.04),-0.41 (-1.87-1.04)
COVID-19 death,Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.02,(0.01-0.06), 97.6,(94.2-99.0),0.02 (0.01-0.06), 97.6 (94.2-99.0),0.46,(-0.51-1.44),0.46 (-0.51-1.44)
COVID-19 death,Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.00,(0.00-0.03), 99.6,(96.8-99.9),0.00 (0.00-0.03), 99.6 (96.8-99.9),-0.81,(-2.84-1.23),-0.81 (-2.84-1.23)
COVID-19 death,Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.01,(0.00-0.05), 98.9,(95.3-99.7),0.01 (0.00-0.05), 98.9 (95.3-99.7),0.65,(-0.91-2.21),0.65 (-0.91-2.21)
COVID-19 death,Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.00,(0.00-0.02), 99.8,(98.3-100.0),0.00 (0.00-0.02), 99.8 (98.3-100.0),-0.41,(-2.44-1.62),-0.41 (-2.44-1.62)
COVID-19 death,BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.00,(0.00-0.02), 99.7,(98.0-100.0),0.00 (0.00-0.02), 99.7 (98.0-100.0),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.01,(0.00-0.02), 99.1,(97.9-99.6),0.01 (0.00-0.02), 99.1 (97.9-99.6),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.01,(0.00-0.01), 99.3,(98.7-99.6),0.01 (0.00-0.01), 99.3 (98.7-99.6),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.01,(0.00-0.01), 99.4,(98.8-99.7),0.01 (0.00-0.01), 99.4 (98.8-99.7),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.01,(0.00-0.01), 99.3,(98.7-99.6),0.01 (0.00-0.01), 99.3 (98.7-99.6),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.00,(0.00-0.01), 99.7,(99.2-99.9),0.00 (0.00-0.01), 99.7 (99.2-99.9),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.00,(0.00-0.00), 99.8,(99.6-99.9),0.00 (0.00-0.00), 99.8 (99.6-99.9),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.00,(0.00-0.02), 99.7,(97.7-100.0),0.00 (0.00-0.02), 99.7 (97.7-100.0),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.01,(0.00-0.02), 99.0,(97.6-99.6),0.01 (0.00-0.02), 99.0 (97.6-99.6),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.01,(0.00-0.02), 99.2,(98.5-99.6),0.01 (0.00-0.02), 99.2 (98.5-99.6),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.01,(0.00-0.01), 99.3,(98.7-99.6),0.01 (0.00-0.01), 99.3 (98.7-99.6),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.01,(0.00-0.01), 99.2,(98.5-99.6),0.01 (0.00-0.01), 99.2 (98.5-99.6),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.00,(0.00-0.01), 99.7,(99.2-99.9),0.00 (0.00-0.01), 99.7 (99.2-99.9),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.00,(0.00-0.00), 99.8,(99.6-99.9),0.00 (0.00-0.00), 99.8 (99.6-99.9),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.00,(0.00-0.02), 99.7,(97.6-100.0),0.00 (0.00-0.02), 99.7 (97.6-100.0),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.01,(0.00-0.03), 98.8,(96.8-99.5),0.01 (0.00-0.03), 98.8 (96.8-99.5),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.01,(0.00-0.02), 99.1,(98.2-99.5),0.01 (0.00-0.02), 99.1 (98.2-99.5),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.01,(0.00-0.01), 99.2,(98.6-99.6),0.01 (0.00-0.01), 99.2 (98.6-99.6),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.01,(0.01-0.02), 99.1,(98.3-99.5),0.01 (0.01-0.02), 99.1 (98.3-99.5),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.00,(0.00-0.01), 99.6,(99.0-99.9),0.00 (0.00-0.01), 99.6 (99.0-99.9),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.00,(0.00-0.01), 99.7,(99.5-99.9),0.00 (0.00-0.01), 99.7 (99.5-99.9),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-9.54,(-11.50--7.59),-9.54 (-11.50--7.59)
COVID-19 death,BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-10.92,(-11.80--10.03),-10.92 (-11.80--10.03)
COVID-19 death,BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.01,(0.00-0.05), 99.4,(95.4-99.9),0.01 (0.00-0.05), 99.4 (95.4-99.9),-0.06,(-2.12-2.01),-0.06 (-2.12-2.01)
COVID-19 death,BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.03,(0.01-0.06), 97.5,(93.8-99.0),0.03 (0.01-0.06), 97.5 (93.8-99.0),1.41,(0.32-2.50),1.41 (0.32-2.50)
COVID-19 death,BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.01,(0.00-0.04), 99.5,(96.3-99.9),0.01 (0.00-0.04), 99.5 (96.3-99.9),-0.31,(-2.37-1.76),-0.31 (-2.37-1.76)
COVID-19 death,BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.01,(0.00-0.04), 99.4,(95.6-99.9),0.01 (0.00-0.04), 99.4 (95.6-99.9),0.77,(-1.44-2.98),0.77 (-1.44-2.98)
COVID-19 death,BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.00,(0.00-0.02), 99.7,(98.2-100.0),0.00 (0.00-0.02), 99.7 (98.2-100.0),0.19,(-1.90-2.27),0.19 (-1.90-2.27)
COVID-19 death,BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-9.52,(-11.48--7.57),-9.52 (-11.48--7.57)
COVID-19 death,BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-10.90,(-11.79--10.01),-10.90 (-11.79--10.01)
COVID-19 death,BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.01,(0.00-0.05), 99.3,(94.8-99.9),0.01 (0.00-0.05), 99.3 (94.8-99.9),-0.07,(-2.14-2.00),-0.07 (-2.14-2.00)
COVID-19 death,BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.03,(0.01-0.07), 97.1,(92.9-98.8),0.03 (0.01-0.07), 97.1 (92.9-98.8),1.40,(0.31-2.50),1.40 (0.31-2.50)
COVID-19 death,BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.01,(0.00-0.04), 99.4,(95.8-99.9),0.01 (0.00-0.04), 99.4 (95.8-99.9),-0.32,(-2.38-1.75),-0.32 (-2.38-1.75)
COVID-19 death,BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.01,(0.00-0.05), 99.3,(95.1-99.9),0.01 (0.00-0.05), 99.3 (95.1-99.9),0.76,(-1.46-2.97),0.76 (-1.46-2.97)
COVID-19 death,BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.00,(0.00-0.02), 99.7,(98.1-100.0),0.00 (0.00-0.02), 99.7 (98.1-100.0),0.19,(-1.89-2.27),0.19 (-1.89-2.27)
COVID-19 death,BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-9.53,(-11.48--7.58),-9.53 (-11.48--7.58)
COVID-19 death,BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-11.07,(-12.01--10.12),-11.07 (-12.01--10.12)
COVID-19 death,BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.01,(0.00-0.05), 99.2,(94.6-99.9),0.01 (0.00-0.05), 99.2 (94.6-99.9),-0.21,(-2.29-1.87),-0.21 (-2.29-1.87)
COVID-19 death,BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.03,(0.01-0.08), 96.8,(92.0-98.7),0.03 (0.01-0.08), 96.8 (92.0-98.7),1.44,(0.34-2.53),1.44 (0.34-2.53)
COVID-19 death,BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.01,(0.00-0.04), 99.4,(95.5-99.9),0.01 (0.00-0.04), 99.4 (95.5-99.9),-0.39,(-2.45-1.67),-0.39 (-2.45-1.67)
COVID-19 death,BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.01,(0.00-0.05), 99.3,(94.9-99.9),0.01 (0.00-0.05), 99.3 (94.9-99.9),0.65,(-1.57-2.86),0.65 (-1.57-2.86)
COVID-19 death,BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.00,(0.00-0.02), 99.7,(97.8-100.0),0.00 (0.00-0.02), 99.7 (97.8-100.0),0.17,(-1.91-2.26),0.17 (-1.91-2.26)
COVID-19 death,ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.01,(0.00-0.03), 99.2,(97.0-99.8),0.01 (0.00-0.03), 99.2 (97.0-99.8),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.01,(0.00-0.02), 99.2,(97.6-99.7),0.01 (0.00-0.02), 99.2 (97.6-99.7),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.02,(0.01-0.03), 98.2,(96.8-98.9),0.02 (0.01-0.03), 98.2 (96.8-98.9),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.03,(0.02-0.04), 97.3,(95.6-98.3),0.03 (0.02-0.04), 97.3 (95.6-98.3),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.01,(0.00-0.02), 98.9,(97.5-99.5),0.01 (0.00-0.02), 98.9 (97.5-99.5),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.01,(0.00-0.03), 98.8,(97.1-99.5),0.01 (0.00-0.03), 98.8 (97.1-99.5),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.01,(0.00-0.02), 99.1,(98.1-99.6),0.01 (0.00-0.02), 99.1 (98.1-99.6),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.01,(0.00-0.03), 99.3,(97.0-99.8),0.01 (0.00-0.03), 99.3 (97.0-99.8),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.01,(0.00-0.02), 99.2,(97.6-99.7),0.01 (0.00-0.02), 99.2 (97.6-99.7),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.02,(0.01-0.03), 98.1,(96.8-98.9),0.02 (0.01-0.03), 98.1 (96.8-98.9),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.03,(0.02-0.04), 97.2,(95.6-98.3),0.03 (0.02-0.04), 97.2 (95.6-98.3),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.01,(0.00-0.02), 98.9,(97.5-99.5),0.01 (0.00-0.02), 98.9 (97.5-99.5),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.01,(0.00-0.03), 98.8,(97.1-99.5),0.01 (0.00-0.03), 98.8 (97.1-99.5),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.01,(0.00-0.02), 99.1,(98.1-99.6),0.01 (0.00-0.02), 99.1 (98.1-99.6),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.01,(0.00-0.04), 99.1,(96.5-99.8),0.01 (0.00-0.04), 99.1 (96.5-99.8),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.01,(0.00-0.03), 99.1,(97.1-99.7),0.01 (0.00-0.03), 99.1 (97.1-99.7),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.02,(0.01-0.04), 97.8,(96.1-98.7),0.02 (0.01-0.04), 97.8 (96.1-98.7),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.03,(0.02-0.06), 96.5,(94.4-97.8),0.03 (0.02-0.06), 96.5 (94.4-97.8),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.01,(0.01-0.03), 98.5,(96.7-99.3),0.01 (0.01-0.03), 98.5 (96.7-99.3),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.01,(0.01-0.04), 98.5,(96.4-99.4),0.01 (0.01-0.04), 98.5 (96.4-99.4),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.01,(0.00-0.02), 99.0,(97.8-99.5),0.01 (0.00-0.02), 99.0 (97.8-99.5),0.00,(NA-NA),0.00 (NA-NA)
COVID-19 death,ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-12.60,(-14.00--11.21),-12.60 (-14.00--11.21)
COVID-19 death,ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.02,(0.00-0.15), 97.8,(84.7-99.7),0.02 (0.00-0.15), 97.8 (84.7-99.7),1.02,(-1.25-3.28),1.02 (-1.25-3.28)
COVID-19 death,ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.01,(0.00-0.08), 98.8,(91.8-99.8),0.01 (0.00-0.08), 98.8 (91.8-99.8),-0.47,(-2.51-1.57),-0.47 (-2.51-1.57)
COVID-19 death,ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-14.01,(-14.52--13.50),-14.01 (-14.52--13.50)
COVID-19 death,ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-12.87,(-13.71--12.03),-12.87 (-13.71--12.03)
COVID-19 death,ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.02,(0.00-0.16), 97.8,(84.2-99.7),0.02 (0.00-0.16), 97.8 (84.2-99.7),0.61,(-1.55-2.77),0.61 (-1.55-2.77)
COVID-19 death,ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-11.60,(-12.43--10.78),-11.60 (-12.43--10.78)
COVID-19 death,ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-12.52,(-13.92--11.13),-12.52 (-13.92--11.13)
COVID-19 death,ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.02,(0.00-0.16), 97.8,(84.3-99.7),0.02 (0.00-0.16), 97.8 (84.3-99.7),1.04,(-1.23-3.31),1.04 (-1.23-3.31)
COVID-19 death,ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.01,(0.00-0.09), 98.8,(91.4-99.8),0.01 (0.00-0.09), 98.8 (91.4-99.8),-0.44,(-2.48-1.60),-0.44 (-2.48-1.60)
COVID-19 death,ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-13.93,(-14.44--13.42),-13.93 (-14.44--13.42)
COVID-19 death,ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-12.79,(-13.63--11.95),-12.79 (-13.63--11.95)
COVID-19 death,ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.02,(0.00-0.16), 97.7,(83.7-99.7),0.02 (0.00-0.16), 97.7 (83.7-99.7),0.65,(-1.50-2.81),0.65 (-1.50-2.81)
COVID-19 death,ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-11.52,(-12.35--10.68),-11.52 (-12.35--10.68)
COVID-19 death,ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-12.48,(-13.87--11.08),-12.48 (-13.87--11.08)
COVID-19 death,ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.03,(0.00-0.20), 97.2,(80.2-99.6),0.03 (0.00-0.20), 97.2 (80.2-99.6),1.08,(-1.19-3.35),1.08 (-1.19-3.35)
COVID-19 death,ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.02,(0.00-0.11), 98.5,(89.1-99.8),0.02 (0.00-0.11), 98.5 (89.1-99.8),-0.38,(-2.42-1.66),-0.38 (-2.42-1.66)
COVID-19 death,ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-13.89,(-14.41--13.37),-13.89 (-14.41--13.37)
COVID-19 death,ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-12.81,(-13.66--11.96),-12.81 (-13.66--11.96)
COVID-19 death,ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.03,(0.00-0.22), 96.9,(77.9-99.6),0.03 (0.00-0.22), 96.9 (77.9-99.6),0.74,(-1.43-2.90),0.74 (-1.43-2.90)
COVID-19 death,ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.00,(0.00-0.00),100.0,(100.0-100.0),0.00 (0.00-0.00),100.0 (100.0-100.0),-11.46,(-12.32--10.61),-11.46 (-12.32--10.61)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.18,(0.15-0.21), 82.4,(78.8-85.4),0.18 (0.15-0.21), 82.4 (78.8-85.4),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.21,(0.18-0.24), 79.1,(75.9-81.9),0.21 (0.18-0.24), 79.1 (75.9-81.9),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.18,(0.16-0.20), 81.8,(79.7-83.8),0.18 (0.16-0.20), 81.8 (79.7-83.8),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.16,(0.14-0.18), 83.9,(82.0-85.7),0.16 (0.14-0.18), 83.9 (82.0-85.7),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.16,(0.14-0.18), 84.0,(82.1-85.7),0.16 (0.14-0.18), 84.0 (82.1-85.7),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.14,(0.12-0.15), 86.4,(84.7-87.9),0.14 (0.12-0.15), 86.4 (84.7-87.9),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.11,(0.11-0.12), 88.6,(87.8-89.4),0.11 (0.11-0.12), 88.6 (87.8-89.4),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.18,(0.15-0.22), 81.7,(77.9-84.8),0.18 (0.15-0.22), 81.7 (77.9-84.8),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.22,(0.19-0.25), 78.1,(74.7-81.0),0.22 (0.19-0.25), 78.1 (74.7-81.0),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.19,(0.17-0.22), 80.6,(78.3-82.6),0.19 (0.17-0.22), 80.6 (78.3-82.6),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.17,(0.16-0.20), 82.5,(80.4-84.4),0.17 (0.16-0.20), 82.5 (80.4-84.4),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.18,(0.16-0.20), 82.4,(80.2-84.3),0.18 (0.16-0.20), 82.4 (80.2-84.3),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.15,(0.13-0.17), 85.0,(83.1-86.7),0.15 (0.13-0.17), 85.0 (83.1-86.7),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.13,(0.12-0.14), 87.3,(86.3-88.2),0.13 (0.12-0.14), 87.3 (86.3-88.2),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.19,(0.16-0.23), 80.7,(76.7-84.0),0.19 (0.16-0.23), 80.7 (76.7-84.0),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.23,(0.20-0.26), 77.2,(73.6-80.2),0.23 (0.20-0.26), 77.2 (73.6-80.2),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.20,(0.18-0.23), 79.8,(77.4-82.0),0.20 (0.18-0.23), 79.8 (77.4-82.0),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.18,(0.16-0.20), 81.7,(79.5-83.7),0.18 (0.16-0.20), 81.7 (79.5-83.7),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.18,(0.16-0.21), 81.7,(79.5-83.7),0.18 (0.16-0.21), 81.7 (79.5-83.7),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.16,(0.14-0.18), 84.3,(82.3-86.1),0.16 (0.14-0.18), 84.3 (82.3-86.1),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.13,(0.12-0.14), 86.7,(85.7-87.7),0.13 (0.12-0.14), 86.7 (85.7-87.7),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.11,(0.05-0.23), 89.1,(76.9-94.8),0.11 (0.05-0.23), 89.1 (76.9-94.8),-0.48,(-1.25-0.29),-0.48 (-1.25-0.29)
"Non-COVID-19
death",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.14,(0.08-0.23), 86.5,(76.5-92.2),0.14 (0.08-0.23), 86.5 (76.5-92.2),-0.43,(-1.00-0.14),-0.43 (-1.00-0.14)
"Non-COVID-19
death",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.18,(0.12-0.25), 82.5,(75.1-87.6),0.18 (0.12-0.25), 82.5 (75.1-87.6),-0.04,(-0.40-0.33),-0.04 (-0.40-0.33)
"Non-COVID-19
death",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.17,(0.12-0.24), 83.0,(76.3-87.7),0.17 (0.12-0.24), 83.0 (76.3-87.7),0.06,(-0.29-0.41),0.06 (-0.29-0.41)
"Non-COVID-19
death",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.16,(0.11-0.22), 84.1,(77.9-88.6),0.16 (0.11-0.22), 84.1 (77.9-88.6),-0.01,(-0.36-0.34),-0.01 (-0.36-0.34)
"Non-COVID-19
death",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.10,(0.07-0.15), 89.6,(84.6-93.0),0.10 (0.07-0.15), 89.6 (84.6-93.0),-0.26,(-0.67-0.15),-0.26 (-0.67-0.15)
"Non-COVID-19
death",Any vaccine,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.10,(0.08-0.12), 90.2,(88.1-91.9),0.10 (0.08-0.12), 90.2 (88.1-91.9),-0.15,(-0.35-0.06),-0.15 (-0.35-0.06)
"Non-COVID-19
death",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.11,(0.05-0.24), 88.8,(76.3-94.7),0.11 (0.05-0.24), 88.8 (76.3-94.7),-0.49,(-1.26-0.28),-0.49 (-1.26-0.28)
"Non-COVID-19
death",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.14,(0.08-0.24), 86.0,(75.7-91.9),0.14 (0.08-0.24), 86.0 (75.7-91.9),-0.45,(-1.02-0.12),-0.45 (-1.02-0.12)
"Non-COVID-19
death",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.18,(0.13-0.26), 81.6,(74.0-87.0),0.18 (0.13-0.26), 81.6 (74.0-87.0),-0.06,(-0.42-0.31),-0.06 (-0.42-0.31)
"Non-COVID-19
death",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.18,(0.13-0.25), 81.9,(74.9-86.9),0.18 (0.13-0.25), 81.9 (74.9-86.9),0.03,(-0.31-0.38),0.03 (-0.31-0.38)
"Non-COVID-19
death",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.17,(0.12-0.24), 83.0,(76.3-87.8),0.17 (0.12-0.24), 83.0 (76.3-87.8),-0.03,(-0.38-0.32),-0.03 (-0.38-0.32)
"Non-COVID-19
death",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.11,(0.08-0.17), 88.8,(83.4-92.4),0.11 (0.08-0.17), 88.8 (83.4-92.4),-0.29,(-0.70-0.12),-0.29 (-0.70-0.12)
"Non-COVID-19
death",Any vaccine,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.11,(0.09-0.13), 89.4,(87.2-91.3),0.11 (0.09-0.13), 89.4 (87.2-91.3),-0.19,(-0.40-0.02),-0.19 (-0.40-0.02)
"Non-COVID-19
death",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.10,(0.05-0.22), 89.6,(77.5-95.2),0.10 (0.05-0.22), 89.6 (77.5-95.2),-0.61,(-1.40-0.18),-0.61 (-1.40-0.18)
"Non-COVID-19
death",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.14,(0.08-0.24), 86.4,(76.2-92.2),0.14 (0.08-0.24), 86.4 (76.2-92.2),-0.52,(-1.09-0.06),-0.52 (-1.09-0.06)
"Non-COVID-19
death",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.19,(0.13-0.27), 80.9,(72.8-86.6),0.19 (0.13-0.27), 80.9 (72.8-86.6),-0.06,(-0.43-0.31),-0.06 (-0.43-0.31)
"Non-COVID-19
death",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.19,(0.14-0.27), 80.5,(73.0-86.0),0.19 (0.14-0.27), 80.5 (73.0-86.0),0.06,(-0.28-0.41),0.06 (-0.28-0.41)
"Non-COVID-19
death",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.18,(0.13-0.25), 82.2,(75.1-87.3),0.18 (0.13-0.25), 82.2 (75.1-87.3),-0.03,(-0.38-0.32),-0.03 (-0.38-0.32)
"Non-COVID-19
death",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.12,(0.08-0.18), 88.2,(82.5-92.0),0.12 (0.08-0.18), 88.2 (82.5-92.0),-0.29,(-0.70-0.13),-0.29 (-0.70-0.13)
"Non-COVID-19
death",Any vaccine,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.11,(0.09-0.13), 89.1,(86.7-91.1),0.11 (0.09-0.13), 89.1 (86.7-91.1),-0.20,(-0.41-0.02),-0.20 (-0.41-0.02)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.12,(0.09-0.15), 88.4,(84.6-91.3),0.12 (0.09-0.15), 88.4 (84.6-91.3),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.12,(0.10-0.16), 87.6,(84.5-90.1),0.12 (0.10-0.16), 87.6 (84.5-90.1),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.11,(0.09-0.13), 88.9,(86.8-90.6),0.11 (0.09-0.13), 88.9 (86.8-90.6),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.10,(0.09-0.12), 89.7,(87.9-91.2),0.10 (0.09-0.12), 89.7 (87.9-91.2),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.12,(0.10-0.14), 88.0,(86.0-89.7),0.12 (0.10-0.14), 88.0 (86.0-89.7),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.09,(0.08-0.11), 90.7,(88.9-92.1),0.09 (0.08-0.11), 90.7 (88.9-92.1),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.11,(0.10-0.12), 89.5,(88.5-90.4),0.11 (0.10-0.12), 89.5 (88.5-90.4),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.13,(0.10-0.17), 87.0,(82.7-90.2),0.13 (0.10-0.17), 87.0 (82.7-90.2),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.14,(0.11-0.18), 85.9,(82.3-88.8),0.14 (0.11-0.18), 85.9 (82.3-88.8),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.13,(0.11-0.15), 87.2,(84.8-89.2),0.13 (0.11-0.15), 87.2 (84.8-89.2),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.12,(0.10-0.14), 88.1,(85.9-89.9),0.12 (0.10-0.14), 88.1 (85.9-89.9),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.14,(0.12-0.16), 86.1,(83.7-88.1),0.14 (0.12-0.16), 86.1 (83.7-88.1),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.11,(0.09-0.13), 89.3,(87.3-91.0),0.11 (0.09-0.13), 89.3 (87.3-91.0),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.11,(0.10-0.13), 88.5,(87.4-89.6),0.11 (0.10-0.13), 88.5 (87.4-89.6),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.14,(0.11-0.19), 85.9,(81.2-89.5),0.14 (0.11-0.19), 85.9 (81.2-89.5),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.15,(0.12-0.19), 84.9,(80.9-88.0),0.15 (0.12-0.19), 84.9 (80.9-88.0),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.14,(0.12-0.17), 86.1,(83.5-88.3),0.14 (0.12-0.17), 86.1 (83.5-88.3),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.13,(0.11-0.15), 87.0,(84.7-89.0),0.13 (0.11-0.15), 87.0 (84.7-89.0),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.15,(0.13-0.18), 84.6,(82.0-86.9),0.15 (0.13-0.18), 84.6 (82.0-86.9),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.12,(0.10-0.14), 88.1,(85.8-90.0),0.12 (0.10-0.14), 88.1 (85.8-90.0),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.13,(0.11-0.14), 87.4,(86.1-88.6),0.13 (0.11-0.14), 87.4 (86.1-88.6),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.05,(0.01-0.19), 95.3,(81.1-98.8),0.05 (0.01-0.19), 95.3 (81.1-98.8),-0.90,(-2.32-0.52),-0.90 (-2.32-0.52)
"Non-COVID-19
death",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.08,(0.03-0.18), 92.4,(81.5-96.8),0.08 (0.03-0.18), 92.4 (81.5-96.8),-0.48,(-1.39-0.43),-0.48 (-1.39-0.43)
"Non-COVID-19
death",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.11,(0.06-0.18), 89.4,(82.1-93.7),0.11 (0.06-0.18), 89.4 (82.1-93.7),-0.05,(-0.59-0.50),-0.05 (-0.59-0.50)
"Non-COVID-19
death",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.10,(0.06-0.17), 89.6,(83.1-93.5),0.10 (0.06-0.17), 89.6 (83.1-93.5),0.01,(-0.50-0.52),0.01 (-0.50-0.52)
"Non-COVID-19
death",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.15,(0.10-0.22), 85.3,(77.9-90.3),0.15 (0.10-0.22), 85.3 (77.9-90.3),0.20,(-0.23-0.64),0.20 (-0.23-0.64)
"Non-COVID-19
death",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.06,(0.03-0.11), 94.1,(89.0-96.8),0.06 (0.03-0.11), 94.1 (89.0-96.8),-0.46,(-1.09-0.18),-0.46 (-1.09-0.18)
"Non-COVID-19
death",BNT162b2,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.09,(0.07-0.11), 91.3,(88.8-93.2),0.09 (0.07-0.11), 91.3 (88.8-93.2),-0.18,(-0.45-0.08),-0.18 (-0.45-0.08)
"Non-COVID-19
death",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.05,(0.01-0.20), 95.0,(79.9-98.7),0.05 (0.01-0.20), 95.0 (79.9-98.7),-0.95,(-2.37-0.46),-0.95 (-2.37-0.46)
"Non-COVID-19
death",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.08,(0.03-0.20), 91.8,(80.2-96.6),0.08 (0.03-0.20), 91.8 (80.2-96.6),-0.54,(-1.45-0.37),-0.54 (-1.45-0.37)
"Non-COVID-19
death",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.12,(0.07-0.19), 88.5,(80.6-93.2),0.12 (0.07-0.19), 88.5 (80.6-93.2),-0.11,(-0.65-0.44),-0.11 (-0.65-0.44)
"Non-COVID-19
death",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.11,(0.07-0.18), 88.6,(81.6-93.0),0.11 (0.07-0.18), 88.6 (81.6-93.0),-0.05,(-0.56-0.46),-0.05 (-0.56-0.46)
"Non-COVID-19
death",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.16,(0.11-0.24), 84.0,(75.9-89.4),0.16 (0.11-0.24), 84.0 (75.9-89.4),0.14,(-0.30-0.58),0.14 (-0.30-0.58)
"Non-COVID-19
death",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.06,(0.03-0.12), 93.6,(88.2-96.6),0.06 (0.03-0.12), 93.6 (88.2-96.6),-0.51,(-1.15-0.12),-0.51 (-1.15-0.12)
"Non-COVID-19
death",BNT162b2,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.09,(0.07-0.12), 90.9,(88.4-92.9),0.09 (0.07-0.12), 90.9 (88.4-92.9),-0.23,(-0.50-0.03),-0.23 (-0.50-0.03)
"Non-COVID-19
death",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.05,(0.01-0.21), 94.7,(78.8-98.7),0.05 (0.01-0.21), 94.7 (78.8-98.7),-0.98,(-2.40-0.44),-0.98 (-2.40-0.44)
"Non-COVID-19
death",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.09,(0.04-0.21), 91.2,(78.6-96.3),0.09 (0.04-0.21), 91.2 (78.6-96.3),-0.54,(-1.45-0.38),-0.54 (-1.45-0.38)
"Non-COVID-19
death",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.13,(0.08-0.22), 87.1,(78.1-92.4),0.13 (0.08-0.22), 87.1 (78.1-92.4),-0.07,(-0.63-0.48),-0.07 (-0.63-0.48)
"Non-COVID-19
death",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.13,(0.08-0.21), 87.1,(79.0-92.0),0.13 (0.08-0.21), 87.1 (79.0-92.0),0.00,(-0.51-0.51),0.00 (-0.51-0.51)
"Non-COVID-19
death",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.18,(0.12-0.28), 81.8,(72.4-88.0),0.18 (0.12-0.28), 81.8 (72.4-88.0),0.17,(-0.28-0.62),0.17 (-0.28-0.62)
"Non-COVID-19
death",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.08,(0.04-0.14), 92.4,(85.9-95.9),0.08 (0.04-0.14), 92.4 (85.9-95.9),-0.45,(-1.10-0.19),-0.45 (-1.10-0.19)
"Non-COVID-19
death",BNT162b2,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.10,(0.07-0.12), 90.4,(87.7-92.6),0.10 (0.07-0.12), 90.4 (87.7-92.6),-0.27,(-0.55-0.00),-0.27 (-0.55-0.00)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.25,(0.19-0.31), 75.5,(68.6-80.8),0.25 (0.19-0.31), 75.5 (68.6-80.8),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.31,(0.26-0.37), 68.9,(62.5-74.2),0.31 (0.26-0.37), 68.9 (62.5-74.2),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.27,(0.23-0.32), 72.8,(68.4-76.6),0.27 (0.23-0.32), 72.8 (68.4-76.6),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.25,(0.22-0.29), 75.0,(70.9-78.5),0.25 (0.22-0.29), 75.0 (70.9-78.5),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.23,(0.20-0.27), 77.1,(73.1-80.4),0.23 (0.20-0.27), 77.1 (73.1-80.4),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.23,(0.20-0.27), 77.0,(73.0-80.4),0.23 (0.20-0.27), 77.0 (73.0-80.4),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.21,(0.19-0.23), 79.3,(76.9-81.5),0.21 (0.19-0.23), 79.3 (76.9-81.5),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.23,(0.18-0.30), 76.7,(70.1-81.8),0.23 (0.18-0.30), 76.7 (70.1-81.8),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.30,(0.25-0.36), 70.2,(64.1-75.3),0.30 (0.25-0.36), 70.2 (64.1-75.3),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.26,(0.23-0.30), 73.8,(69.6-77.4),0.26 (0.23-0.30), 73.8 (69.6-77.4),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.24,(0.21-0.28), 75.9,(72.0-79.3),0.24 (0.21-0.28), 75.9 (72.0-79.3),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.22,(0.19-0.26), 78.0,(74.2-81.2),0.22 (0.19-0.26), 78.0 (74.2-81.2),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.22,(0.19-0.26), 77.9,(74.1-81.2),0.22 (0.19-0.26), 77.9 (74.1-81.2),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.21,(0.18-0.23), 79.5,(77.1-81.7),0.21 (0.18-0.23), 79.5 (77.1-81.7),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.24,(0.19-0.31), 76.0,(69.1-81.4),0.24 (0.19-0.31), 76.0 (69.1-81.4),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.32,(0.26-0.39), 68.3,(61.3-74.0),0.32 (0.26-0.39), 68.3 (61.3-74.0),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.27,(0.23-0.32), 72.7,(68.2-76.6),0.27 (0.23-0.32), 72.7 (68.2-76.6),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.25,(0.22-0.29), 74.9,(70.7-78.5),0.25 (0.22-0.29), 74.9 (70.7-78.5),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.23,(0.19-0.28), 76.9,(72.3-80.7),0.23 (0.19-0.28), 76.9 (72.3-80.7),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.22,(0.19-0.26), 78.1,(74.2-81.4),0.22 (0.19-0.26), 78.1 (74.2-81.4),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Not immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.21,(0.19-0.24), 78.7,(76.1-81.0),0.21 (0.19-0.24), 78.7 (76.1-81.0),0.00,(NA-NA),0.00 (NA-NA)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",1-3,0.19,(0.08-0.47), 81.0,(53.2-92.2),0.19 (0.08-0.47), 81.0 (53.2-92.2),-0.25,(-1.18-0.68),-0.25 (-1.18-0.68)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",4-7,0.20,(0.10-0.41), 79.9,(59.2-90.1),0.20 (0.10-0.41), 79.9 (59.2-90.1),-0.44,(-1.17-0.30),-0.44 (-1.17-0.30)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",8-14,0.24,(0.15-0.39), 75.7,(61.2-84.7),0.24 (0.15-0.39), 75.7 (61.2-84.7),-0.11,(-0.60-0.38),-0.11 (-0.60-0.38)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",15-21,0.24,(0.16-0.37), 75.8,(62.6-84.3),0.24 (0.16-0.37), 75.8 (62.6-84.3),-0.03,(-0.49-0.43),-0.03 (-0.49-0.43)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",22-28,0.15,(0.09-0.26), 84.9,(74.4-91.1),0.15 (0.09-0.26), 84.9 (74.4-91.1),-0.42,(-0.97-0.13),-0.42 (-0.97-0.13)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",29-35,0.19,(0.11-0.31), 81.1,(68.9-88.5),0.19 (0.11-0.31), 81.1 (68.9-88.5),-0.20,(-0.72-0.32),-0.20 (-0.72-0.32)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,1,"Region-stratified Cox model, with no further adjustment",36+,0.17,(0.13-0.24), 82.7,(76.4-87.4),0.17 (0.13-0.24), 82.7 (76.4-87.4),-0.18,(-0.51-0.15),-0.18 (-0.51-0.15)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",1-3,0.18,(0.07-0.45), 81.7,(55.0-92.5),0.18 (0.07-0.45), 81.7 (55.0-92.5),-0.24,(-1.17-0.69),-0.24 (-1.17-0.69)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",4-7,0.19,(0.10-0.39), 80.5,(60.5-90.4),0.19 (0.10-0.39), 80.5 (60.5-90.4),-0.42,(-1.15-0.31),-0.42 (-1.15-0.31)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",8-14,0.24,(0.15-0.38), 76.2,(62.2-85.1),0.24 (0.15-0.38), 76.2 (62.2-85.1),-0.10,(-0.59-0.39),-0.10 (-0.59-0.39)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",15-21,0.24,(0.15-0.37), 76.2,(63.3-84.6),0.24 (0.15-0.37), 76.2 (63.3-84.6),-0.01,(-0.47-0.45),-0.01 (-0.47-0.45)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",22-28,0.15,(0.09-0.25), 85.2,(74.8-91.3),0.15 (0.09-0.25), 85.2 (74.8-91.3),-0.40,(-0.95-0.16),-0.40 (-0.95-0.16)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",29-35,0.19,(0.11-0.31), 81.5,(69.5-88.8),0.19 (0.11-0.31), 81.5 (69.5-88.8),-0.18,(-0.70-0.35),-0.18 (-0.70-0.35)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,2,"Region-stratified Cox model, with adjustment for baseline confounders",36+,0.17,(0.13-0.24), 82.8,(76.4-87.5),0.17 (0.13-0.24), 82.8 (76.4-87.5),-0.18,(-0.51-0.16),-0.18 (-0.51-0.16)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",1-3,0.14,(0.05-0.39), 86.3,(60.9-95.2),0.14 (0.05-0.39), 86.3 (60.9-95.2),-0.56,(-1.64-0.52),-0.56 (-1.64-0.52)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",4-7,0.18,(0.08-0.37), 82.5,(62.8-91.7),0.18 (0.08-0.37), 82.5 (62.8-91.7),-0.59,(-1.37-0.19),-0.59 (-1.37-0.19)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",8-14,0.20,(0.12-0.33), 79.8,(67.1-87.7),0.20 (0.12-0.33), 79.8 (67.1-87.7),-0.30,(-0.82-0.21),-0.30 (-0.82-0.21)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",15-21,0.26,(0.17-0.40), 74.3,(60.2-83.4),0.26 (0.17-0.40), 74.3 (60.2-83.4),0.02,(-0.44-0.49),0.02 (-0.44-0.49)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",22-28,0.13,(0.08-0.23), 86.6,(76.7-92.3),0.13 (0.08-0.23), 86.6 (76.7-92.3),-0.55,(-1.13-0.04),-0.55 (-1.13-0.04)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",29-35,0.19,(0.12-0.32), 80.7,(68.1-88.4),0.19 (0.12-0.32), 80.7 (68.1-88.4),-0.13,(-0.66-0.40),-0.13 (-0.66-0.40)
"Non-COVID-19
death",ChAdOx1,Immunocompromised,4,"Region-stratified marginal structural Cox model, with adjustment for baseline and time-varying confounders",36+,0.17,(0.13-0.24), 82.6,(75.9-87.4),0.17 (0.13-0.24), 82.6 (75.9-87.4),-0.20,(-0.55-0.14),-0.20 (-0.55-0.14)
